Form 8-K - Current report:
SEC Accession No. 0001641172-25-026676
Filing Date
2025-09-05
Accepted
2025-09-05 11:53:14
Documents
15
Period of Report
2025-09-04
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 46100
2 GRAPHIC form8-k_001.jpg GRAPHIC 5583
  Complete submission text file 0001641172-25-026676.txt   273253

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE cycc-20250904.xsd EX-101.SCH 3749
4 XBRL DEFINITION FILE cycc-20250904_def.xml EX-101.DEF 26590
5 XBRL LABEL FILE cycc-20250904_lab.xml EX-101.LAB 36640
6 XBRL PRESENTATION FILE cycc-20250904_pre.xml EX-101.PRE 25214
18 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5753
Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Filer) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-50626 | Film No.: 251295592
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)